Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Puma Biotechnology | Evaluate
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
THE FACES OF BREAST CANCER
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Partners of the Pierre Fabre Group: from health to beauty
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Partners of the Pierre Fabre Group: from health to beauty
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotech Expands Pierre Fabre License to Add Countries
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Accord entre Pierre Fabre et Puma Biotechnology
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
